BBLG
Bone Biologics Corp
NASDAQ: BBLG · HEALTHCARE · BIOTECHNOLOGY
$1.31
+0.38% today
Updated 2026-04-30
Market cap
$2.44M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.65
Dividend yield
—
52W range
$1 – $7
Volume
0.0M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$22.20
+1594.66%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-714767.00
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-1.48M | $-8.95M | $-4.11M | $-3.11M | $-684643.00 |
| EPS | — | — | — | — | $-2.65 |
| Free cash flow | $-3.57M | $-9.56M | $-4.12M | $-2.69M | $-714767.00 |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Bone Biologics Corp trades at $1.31. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.
Frequently asked questions
What is Bone Biologics Corp's stock price?
Bone Biologics Corp (BBLG) trades at $1.31.
Is Bone Biologics Corp overvalued?
Smart Value Score 26/100 (Grade F, Strong Sell).
What is the price target of Bone Biologics Corp (BBLG)?
The analyst target price is $22.20, representing +1594.7% upside from the current price of $1.31.
Piotroski F-Score?
3/9 — weak financial health.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-70.20%
Beta0.37
50D MA$1.23
200D MA$1.88
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—